References.
1. Okazaki T, Shinagawa S, Mikage H. Vasculitis syndrome—diagnosis and therapy. J Gen Fam Med. 2017 Mar 24;18(2):72–8.
2. Moura MC, Baqir M. A possible case of statin-induced vasculitis mimicking eosinophilic granulomatosis with polyangiitis. Rheumatology. 2020 Dec 1;59(12):e138–9.
3. Suresh E. Diagnostic approach to patients with suspected vasculitis. Postgrad Med J. 2006 Aug;82(970):483–8.
4. Sen D, Rosenstein ED, Kramer N. ANCA-positive vasculitis associated with simvastatin/ezetimibe: expanding the spectrum of statin-induced autoimmunity? Int J Rheum Dis. 2010 Aug;13(3):e29-31.
5. Moura MC, Baqir M. A possible case of statin-induced vasculitis mimicking eosinophilic granulomatosis with polyangiitis. Rheumatology. 2020 Dec 1;59(12):e138–9.
6. T P, T K, S S, D V, S R, S GN. Atorvastatin Induced Vasculitis. Indian J Pharm Pract. 2014 Sep 30;7(3):75–7.
7. Kostapanos MS, Liberopoulos EN, Elisaf MS. Statin Pleiotropy Against Renal Injury. J Cardiometab Syndr. 2009;4(1):E4–9.
8. Davignon J. Beneficial Cardiovascular Pleiotropic Effects of Statins. Circulation. 2004 Jun 15;109(23_suppl_1):III–39.
9. Schaafsma D, Dueck G, Ghavami S, Kroeker A, Mutawe MM, Hauff K, et al. The Mevalonate Cascade as a Target to Suppress Extracellular Matrix Synthesis by Human Airway Smooth Muscle. Am J Respir Cell Mol Biol. 2011 Mar;44(3):394–403.
10. Schaafsma D, McNeill KD, Mutawe MM, Ghavami S, Unruh H, Jacques E, et al. Simvastatin inhibits TGFβ1-induced fibronectin in human airway fibroblasts. Respir Res. 2011 Dec 1;12(1):113.
11. Garrett IR, Gutierrez G, Mundy GR. Statins and Bone Formation. Curr Pharm Des. 2001 May 1;7(8):715–36.
12. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, et al. Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways. Circulation. 2003 Jul 29;108(4):426–31.
13. Jain MK, Ridker PM. Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. Nat Rev Drug Discov. 2005 Dec;4(12):977–87.
14. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001 Jul 4;286(1):64–70.
15. Ahmadi M, Amiri S, Pecic S, Machaj F, Rosik J, Łos MJ, et al. Pleiotropic effects of statins: A focus on cancer. Biochim Biophys Acta BBA - Mol Basis Dis. 2020 Dec 1;1866(12):165968.
16. Forcadell-Peris MJ, de Diego-Cabanes C. [Rhabdomyolysis secondary to simvastatin and phenofibrate]. Semergen. 2014 Jun;40(4):e91-94.
17. Noël B, Panizzon RG. Lupus-like syndrome associated with statin therapy. Dermatol Basel Switz. 2004;208(3):276–7.
18. John SG, Thorn J, Sobonya R. Statins as a potential risk factor for autoimmune diseases: a case report and review. Am J Ther. 2014 Aug;21(4):e94-96.
19. Gras-Champel V, Masmoudi I, Batteux B, Merle PE, Liabeuf S, Masmoudi K. Statin-associated myasthenia: A case report and literature review. Therapie. 2020 Jun;75(3):301–9.
20. Anchan S. Product Monograph. 2003;46.
21. Pastori D, Farcomeni A, Milanese A, Del Sole F, Menichelli D, Hiatt WR, et al. Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Thromb Haemost. 2020 May;120(05):866–75.
22. Bouiller K, Audia S, Devilliers H, Collet E, Aubriot MH, Leguy-Seguin V, et al. Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement: A retrospective study in 112 patients. Medicine (Baltimore). 2016 Jul;95(28):e4238.
23. Fauci AS, Haynes B, Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med. 1978 Nov;89(5 Pt 1):660–76.
24. Tai YJ, Chong AH, Williams RA, Cumming S, Kelly RI. Retrospective analysis of adult patients with cutaneous leukocytoclastic vasculitis. Australas J Dermatol. 2006 May;47(2):92–6.
25. Ekenstam Eaf null, Callen JP. Cutaneous leukocytoclastic vasculitis. Clinical and laboratory features of 82 patients seen in private practice. Arch Dermatol. 1984 Apr;120(4):484–9.
26. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol. 2003 Mar;48(3):311–40.
27. Byun JW, Song HJ, Kim L, Shin JH, Choi GS. Predictive factors of relapse in adult with Henoch-Schönlein purpura. Am J Dermatopathol. 2012 Apr;34(2):139–44.
28. Alalwani M, Billings SD, Gota CE. Clinical significance of immunoglobulin deposition in leukocytoclastic vasculitis: a 5-year retrospective study of 88 patients at cleveland clinic. Am J Dermatopathol. 2014 Sep;36(9):723–9.
29. Lee HY, Tay LK, Thirumoorthy T, Pang SM. Cutaneous adverse drug reactions in hospitalised patients. Singapore Med J. 2010 Oct;51(10):767–74.
30. T et al. - 2014 - Atorvastatin Induced Vasculitis.pdf [Internet]. [cited 2022 Apr 24]. Available from: https://ijopp.org/sites/default/files/10.5530ijopp.7.3.13.pdf
31. Lipitor and Leukocytoclastic vasculitis, a phase IV clinical study of FDA data - eHealthMe [Internet]. [cited 2022 Apr 24]. Available from: https://www.ehealthme.com/ds/lipitor/leukocytoclastic-vasculitis/
32. Haroon M, Devlin J. A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clin Rheumatol. 2008 Dec;27 Suppl 2:S75-77.